Endogenous regeneration and repair mechanisms are responsible for replacing dead and damaged cells to maintain or enhance tissue and organ function. One of the best examples of endogenous repair mechanisms involves skeletal muscle, which has innate regenerative capacity (for reviews, see Refs. [@B1][@B2][@B3]--[@B4]). Skeletal muscle repair begins with satellite cells, a heterogeneous population of mitotically quiescent cells located in the basal lamina that surrounds adult skeletal myofibers ([@B5], [@B6]), that, when activated, rapidly proliferate ([@B7]). The progeny of activated satellite cells, known as myogenic precursor cells or myoblasts, undergo several rounds of division prior to withdrawal from the cell cycle. This is followed by fusion to form terminally differentiated multinucleated myotubes and skeletal myofibers ([@B7], [@B8]). These cells effectively repair or replace damaged cells or contribute to an increase in skeletal muscle mass.

The molecular mechanisms that regulate differentiation of satellite cells and myoblasts toward myofibers are not fully understood, although it is known that the cell surface proteome plays an important biological role in skeletal muscle differentiation. Examples include how cell surface proteins modulate myoblast elongation, orientation, and fusion (for a review, see Ref. [@B8]). The organization and fusion of myoblasts is mediated, in part, by cadherins (for reviews, see Refs. [@B9] and [@B10]), which enhance skeletal muscle differentiation and are implicated in myoblast fusion ([@B11]). Neogenin, another cell surface protein, is also a likely regulator of myotube formation via the netrin ligand signal transduction pathway ([@B12], [@B13]), and the family of sphingosine 1-phosphate receptors (Edg receptors) are known key signal transduction molecules involved in regulating myogenic differentiation ([@B14][@B15][@B16]--[@B17]). Given the important role of these proteins, identifying and characterizing the cell surface proteins present on myoblasts in a more comprehensive approach could provide insights into the molecular mechanisms involved in skeletal muscle development and repair. The identification of naturally occurring cell surface proteins (*i.e.* markers) could also foster the enrichment and/or characterization of cell intermediates during differentiation that could be useful therapeutically.

Although it is possible to use techniques such as flow cytometry, antibody arrays, and microscopy to probe for known proteins on the cell surface in discrete populations, these methods rely on *a priori* knowledge of the proteins present on the cell surface and the availability/specificity of an antibody. Proteomics approaches coupled with mass spectrometry offer an alternative approach that is antibody-independent and allows for the *de novo* discovery of proteins on the surface. One approach, which was used in the current study, exploits the fact that a majority of the cell surface proteins are glycosylated ([@B18]). The method uses hydrazide chemistry ([@B19]) to immobilize and enrich for glycoproteins/glycopeptides, and previous studies using this chemistry have successfully identified soluble glycoproteins ([@B20][@B21][@B22][@B23]--[@B24]) as well as cell surface glycoproteins ([@B25][@B26][@B27]--[@B28]). A recently optimized hydrazide chemistry strategy by Wollscheid *et al.* ([@B29]) termed cell surface capturing (CSC)[^1^](#G1){ref-type="fn"} technology, reports the ability to identify cell surface (plasma membrane) proteins specifically with little (\<15%) contamination from non-cell surface proteins. The specificity stems from the fact that the oligosaccharide structure is labeled using membrane-impermeable reagents while the cells are intact rather than after cell lysis. Consequently, only extracellular oligosaccharides are labeled and subsequently captured. Utilizing information regarding the glycosylation site then allows for a rapid elimination of nonspecifically captured proteins (*i.e.* non-cell surface proteins) during the data analysis process, a feature that makes this approach unique to methods where no label or tag is used. Additionally, the CSC technology provides information about glycosylation site occupancy (*i.e.* whether a potential *N*-linked glycosylation site is actually glycosylated), which is important for determining the protein orientation within the membrane and, therefore, antigen selection and antibody design.

To uncover information about the cell surface of myoblasts and to identify potential markers of myoblast differentiation, we used the CSC technology on the mouse myoblast C2C12 cell line model system ([@B30], [@B31]). This adherent cell line derived from satellite cells has routinely been used as a model for skeletal muscle development (*e.g.* Refs. [@B1], [@B32], and [@B33]), skeletal muscle differentiation (*e.g.* Refs. [@B34][@B35]--[@B36]), and studying muscular dystrophy (*e.g.* Refs. [@B37][@B38]--[@B39]). Additionally, these cells have been used in cell-based therapies (*e.g.* Refs. [@B40][@B41]--[@B42]). Using the CSC technology, 128 cell surface *N*-linked glycoproteins were identified, including several that were found to change in overall abundance as the myoblasts differentiate toward myotubes. The current data also confirmed the occupancy of 235 *N*-linked glycosites of which 226 were previously unconfirmed. The new information provided by the current study is expected to facilitate the development of useful tools for studying the differentiation of myoblasts toward myotubes.

EXPERIMENTAL PROCEDURES
=======================

### 

#### Cell Culture

Mouse myoblasts (C2C12 cell line) were cultured as described previously ([@B43], [@B44]). C2C12 cells were cultivated in growth medium (Dulbecco\'s modified Eagle\'s medium, [l]{.smallcaps}-Glu, penicillin/streptomycin, 20% fetal bovine serum (FBS), 4.5g/liter glucose) in 5% CO~2~ and passaged at 70--80% confluency to maintain the undifferentiated myoblast population. Three biological replicates of undifferentiated C2C12 cells at ∼70% confluency were used. For differentiation, cells were switched under confluent conditions (\>70--80%) to low serum conditions (5% FBS).

#### CSC Technology

Approximately 1 × 10^8^ cells per biological replicate were taken through the CSC technology work flow as reported previously ([@B28], [@B29]) ([Fig. 1](#F1){ref-type="fig"}). Cells were washed twice with labeling buffer (1× PBS (Quality Biological, Gaithersburg, MD), pH 6.5, 0.1% (v/v) FBS (Invitrogen)) followed by treatment for 15 min in 1.5 m[m]{.smallcaps} sodium *meta*-periodate (Pierce) in labeling buffer at 4 °C. Cells were washed with labeling buffer, collected, and centrifuged at 225 × *g* for 5 min at 25 °C. The pelleted cells were resuspended in 2.5 mg/ml biocytin hydrazide (Biotium, Hayward, CA) in labeling buffer for 1 h at 4 °C with gentle agitation, then washed with 1× PBS, and pelleted as above. Cells were resuspended in lysis buffer (10 m[m]{.smallcaps} Tris, pH 7.5, 0.5 m[m]{.smallcaps} MgCl~2~) and homogenized using a Dounce homogenizer. Cell lysate was centrifuged at 2500 × *g* for 10 min at 4 °C to remove the nucleus. The supernatant, containing the membranes, was centrifuged at 210,000 × *g* for 16 h at 4 °C. The membrane pellet was washed with 25 m[m]{.smallcaps} Na~2~CO~3~, resuspended in lysis buffer, and centrifuged at 210,000 × *g* for 30 min at 4 °C. The pellet was resuspended by sonication in 100 m[m]{.smallcaps} NH~4~HCO~3~, 5 m[m]{.smallcaps} tris(2-carboxyethyl)phosphine (Sigma), 0.1% (v/v) Rapigest (Waters). Proteins were then alkylated with 10 m[m]{.smallcaps} iodoacetamide for 30 min in the dark at 25 °C. The sample was then incubated with 1 μg of glycerol-free endoproteinase Lys-C (Calbiochem) at 37 °C for 4 h with end-over-end rotation and then with 20 μg of proteomics grade trypsin (Promega, Madison, WI) at 37 °C for 16 h with end-over-end rotation. The enzymes were inactivated by heating at 100 °C for 10 min followed by the addition of 10 μl of 1× Complete protease inhibitor mixture (Roche Applied Science). The peptide mixture was incubated with a 500-μl bead slurry of UltraLink Immobilized Streptavidin PLUS (Pierce) for 1 h at 25 °C. The beads were sequentially washed with the following: 5 [m]{.smallcaps} NaCl, 100 m[m]{.smallcaps} NH~4~HCO~3~, 5 [m]{.smallcaps} NaCl, 100 m[m]{.smallcaps} Na~2~CO~3~, 80% isopropanol, and 100 m[m]{.smallcaps} NH~4~HCO~3~. The beads were resuspended in 100 m[m]{.smallcaps} NH~4~HCO~3~ and 500 units of glycerol-free endoproteinase peptide-*N*-glycosidase F (New England Biolabs, Ipswich, MA) and incubated at 37 °C for 16 h with end-over-end rotation to release the peptides from the beads. The collected peptides were desalted and concentrated using a C~18~ UltraMicroSpin™ column (Nest Group, Southborough, MA) according to the manufacturer\'s instructions. In general, 1 × 10^8^ cells provided sufficient peptide quantity for two to three individual LC-MS/MS analyses.

![**Schema of CSC technology for identifying *N*-linked glycoproteins.** Overview of the experimental work flow for enriching and identifying cell surface *N*-linked glycopeptides. *IPI*, International Protein Index; *PNGaseF*, peptide-*N*-glycosidase F.](zjw0110934880001){#F1}

#### Mass Spectrometry

For each biological replicate (*n* = 3), two technical replicates were analyzed by LC-MS/MS using either an LTQ-Orbitrap (Thermo, Waltham, MA) or an LTQ-FT (Thermo). For the LTQ-Orbitrap, desalted peptides were resuspended in 12 μl of 0.1% (v/v) aqueous formic acid (FA). Two times 5 μl were injected and analyzed on an Agilent 1200 nano-LC system (Agilent, Santa Clara, CA) connected to an LTQ-Orbitrap mass spectrometer (Thermo) equipped with a nanoelectrospray ion source (Thermo). Peptides were separated on a BioBasic (New Objective, Woburn, MA) C~18~ reversed phase HPLC column (75 μm × 10 cm) using a linear gradient from 5% B to 65% B in 60 min at a flow rate of 300 nl/min where mobile phase A was composed of 0.1% (v/v) aqueous FA and mobile phase B was 90% acetonitrile, 0.1% FA in water. Each MS1 scan was followed by CID (acquired in the LTQ part) of the five most abundant precursor ions with dynamic exclusion for 30 s. Only MS1 signals exceeding 10,000 counts triggered the MS2 scans. For MS1, 2 × 10^5^ ions were accumulated in the Orbitrap over a maximum time of 500 ms and scanned at a resolution of 60,000 full-width half-maximum (at 400 *m*/*z*). MS2 spectra (via CID) were acquired in normal scan mode in the LTQ using a target setting of 10^4^ ions and an accumulation time of 30 ms. The normalized collision energy was set to 35%, and one microscan was acquired for each spectrum. For the LTQ-FT, desalted peptides were resuspended in 12 μl of 0.1% (v/v) aqueous FA. Two times 4 μl were injected and analyzed on a Tempo™ Nano 1D+ HPLC system (Applied Biosystems/MDS Sciex, Foster City, CA) connected to a 7-tesla Finnigan LTQ-FT-ICR instrument (Thermo) equipped with a nanoelectrospray ion source (Thermo) using a C~18~ reverse phase HPLC column (75 μm × 15 cm) packed in house (Magic C~18~ AQ 3 μm; Michrom Bioresources, Auburn, CA) using a linear gradient from 4% B to 35% B in 60 min at a flow rate of 300 nl/min where mobile phase A was composed of 0.15% aqueous FA and mobile phase B was 98% (v/v) acetonitrile, 0.15% (v/v) FA in water. Each MS1 scan (acquired in the ICR cell) was followed by CID (acquired in the LTQ) of the five most abundant precursor ions with dynamic exclusion for 30 s. Only MS1 signals exceeding 150 counts were allowed to trigger MS2 scans with wideband activation disabled. For MS1, 3 × 10^6^ ions were accumulated in the ICR cell over a maximum time of 500 ms and scanned at a resolution of 100,000 full-width half-maximum (at 400 *m*/*z*). MS2 spectra were acquired in normal scan mode with a target setting of 10^4^ ions and an accumulation time of 100 ms. Singly charged ions and ions with unassigned charge state were excluded from triggering MS2 events. The normalized collision energy was set to 32%, and one microscan was acquired for each spectrum.

#### Mass Spectrometry Database Search

Raw MS data were searched against the International Protein Index mouse v3.47 database ([@B45]) (55,298 entries; August 26, 2008) using Sorcerer 2™-SEQUEST® (Sage-N Research, Milpitas, CA) with postsearch analysis performed using the Trans-Proteome Pipeline, implementing PeptideProphet ([@B46]) and ProteinProphet ([@B47]) algorithms. All raw data peak extraction was performed using Sorcerer 2-SEQUEST default settings. Database search parameters were as follows: semienzyme digest using trypsin (after Lys or Arg) with up to two missed cleavages; monoisotopic precursor mass range of 400--4500 amu; and oxidation (Met), carbamidomethylation (Cys), and deamidation (Asn) allowed as differential modifications. Peptide mass tolerance was set to 50 ppm, fragment mass tolerance was set to 1 amu, fragment mass type was set to monoisotopic, and the maximum number of modifications was set to four per peptide. Advanced search options that were enabled included the following: XCorr score cutoff of 1.5, isotope check using a mass shift of 1.003355 amu, keep the top 2000 preliminary results for final scoring, display up to 200 peptide results in the result file, display up to five full protein descriptions in the result file, and display up to one duplicate protein reference in the result file. Error rates (false discovery rates) and protein probabilities (*p*) were calculated by ProteinProphet. Raw data from all three biological replicates were combined into a single database search.

#### Protein Data Processing, Redundancy Removal, and Database Presentation

The ProteinProphet interact-prot.xml result files were input into ProteinCenter (Proxeon Bioinformatics, Odense, Denmark) and filtered to contain only proteins with protein probability scores of *p* \> 0.48. To prevent redundancy in protein identifications, proteins were grouped according to "indistinguishable proteins," resulting in 128 protein groups. For the final database, isoform notation is provided only when a peptide that is unique to a specific protein isoform was identified. The protein list in [supplemental Table S1](http://www.mcponline.org/cgi/content/full/M900195-MCP200/DC1) displays only those proteins identified by peptides containing an observed deamidation at the asparagine(s) within the conserved sequence motif for *N*-linked glycosylation: asparagine (N) followed by any amino acid except proline (*X*) followed by serine (S) or threonine (T), N*X*(S/T). Membrane topology predictions were obtained from three different prediction algorithms: publicly available versions of HMMTOP v2.0 ([@B48], [@B49]) and SOSUI v1.11 ([@B50]) and TMAP ([@B51]), which is integrated into ProteinCenter.

#### Consideration of Single Peptide Identifications

In this type of sample processing, the number of peptides identified for each protein is completely dependent upon the number of potential *N*-linked glycosylation sites and whether the glycosylation site is within a tryptic peptide of suitable *m*/*z* for MS analysis. For this reason, proteins identified by a single glycopeptide were not automatically excluded; rather, great care was taken to appropriately evaluate and present the data for these identifications, which may fall into two categories. First, there are identifications for which a single peptide sequence was observed \>2 times (either multiple observations of the same charge state or as multiple charge states). This accounts for the majority of identifications based on a single peptide sequence. Second, there were several proteins for which a single peptide was observed ≤2 times. For identifications from the latter category, the annotated MS/MS spectra are provided in [supplemental Table S8c](http://www.mcponline.org/cgi/content/full/M900195-MCP200/DC1). To ensure specificity for the proteins reported, the peptide sequence for any "single peptide identification" was searched (via BLAST) against NCBInr to ensure that it mapped (with 100% homology) to only the protein reported. In [supplemental Table S1](http://www.mcponline.org/cgi/content/full/M900195-MCP200/DC1) the protein identifications are sorted by false discovery rate (*i.e.* confidence), and the [supplemental information](http://www.mcponline.org/cgi/content/full/M900195-MCP200/DC1) contains all details regarding the peptides identified ([supplemental Table S8](http://www.mcponline.org/cgi/content/full/M900195-MCP200/DC1)), including spectra for single peptide identifications when appropriate.

#### Comparison with Previous Studies of C2C12 Differentiation

ProteinCenter was used to compare the experimentally derived data with data imported from the literature (current through December 2008). ProteinCenter clusters equivalent protein names into a single descriptor based on the amino acid sequence, allowing for an accurate comparison among multiple data sets regardless of the database searched. To compare the proteomics data, the accession numbers of the proteins reported by Tannu *et al.* ([@B52]), Kislinger *et al.* ([@B53]), and Capkovic *et al.* ([@B54]), as provided by the authors, were input directly into ProteinCenter. To compare the gene expression data, the list of detected genes as provided by Moran *et al.* ([@B55]) and Tomczak *et al.* ([@B56]) were converted to International Protein Index or Swiss-Prot protein accession numbers using either the Protein Identifier Cross-Reference Service ([@B57]) or IDconverter ([@B58]), and these protein accession numbers were imported into ProteinCenter. For Tomczak *et al.* ([@B56]) data, 103 of 2896 probes could not be assigned to protein accession numbers and are largely expressed sequence tags. For Moran *et al.* ([@B55]) data, only the 629 differentially regulated genes were compared as not all 11,000 that were probed were provided by the authors. Of these, four could not be assigned to protein accession numbers. In ProteinCenter, the protein accession lists for all data were clustered by 80% homology at the amino acid level. A summary of the previous studies with which the current data were compared can be found in [supplemental Table S3](http://www.mcponline.org/cgi/content/full/M900195-MCP200/DC1).

#### Western Blotting

Antibodies were obtained for β-sarcoglycan (Novocastra; NCL-L-b-SARC), aquaporin 1 (Chemicon International, Temecula, CA; AB2219), and cadherin 2 (N-cadherin, CD325; BD Biosciences, San Jose, CA; 610920). For Western blot loading controls, topoisomerase I monoclonal antibody (BD Biosciences; 556597) was used. Cells were lysed in Laemmli buffer, and corresponding amounts of total protein (15--50 μg, determined via BCA assay (Pierce); see [Fig. 5](#F5){ref-type="fig"}) were separated on a 4--12% NuPAGE Bis-Tris gel (Invitrogen) according to the manufacturer\'s standard protocol. The following antibody dilutions were used to detect the protein of interest: anti-aquaporin-1 rabbit polyclonal, 1:1000 dilution; anti-β-sarcoglycan mouse monoclonal, 1:100 dilution; anti-cadherin 2 mouse monoclonal, 1:5000; and anti-topoisomerase I mouse monoclonal, 1:1000 dilution. Blots were developed with Amersham Biosciences ECL™ Western blotting detection reagent (GE Healthcare) according to the manufacturer\'s protocol.

RESULTS
=======

### 

#### Cells

The mouse myoblast C2C12 cell line was cultivated in medium containing high serum (20% FBS) and high glucose (4.5 g/liter). Under these conditions, cells maintained an undifferentiated fibroblast-like morphology with a single nucleus per cell, and no myotube formation was observed. Under confluent conditions (\>80%) and after switching to low serum conditions (5% FBS), the cells spontaneously fused and formed myotubes, thus confirming their utility for studying the differentiation of non-muscle myoblast cells to skeletal muscle cells ([Fig. 2](#F2){ref-type="fig"}).

![**Images of myoblasts.** Bright field images of a monolayer of undifferentiated and mononuclear C2C12 myoblasts cultivated in high serum (20% FBS) (*A*) and a higher magnification of multinucleated C2C12 myotubes after differentiation for 5 days in low serum conditions (5% FBS) (*B*) are shown.](zjw0110934880002){#F2}

#### Database of Cell Surface N-Linked Glycoproteins on Undifferentiated C2C12 Cells

The list of cell surface *N*-linked glycoproteins identified in the present study is presented in [supplemental Table S1](http://www.mcponline.org/cgi/content/full/M900195-MCP200/DC1), and detailed information regarding all of the peptides attributed to each protein can be found in the supporting information ([supplemental Table S8](http://www.mcponline.org/cgi/content/full/M900195-MCP200/DC1)). A total of 128 *N*-linked cell surface glycoproteins were identified with probability scores of *p* \> 0.48. Of these, 114 had scores of *p* \> 0.9, corresponding to a false discovery rate of 1.1% as calculated by ProteinProphet ([supplemental Table S4](http://www.mcponline.org/cgi/content/full/M900195-MCP200/DC1)). Thirty-six proteins correspond to cluster of differentiation (CD) molecules ([@B59]), and all of the proteins listed in [supplemental Table S1](http://www.mcponline.org/cgi/content/full/M900195-MCP200/DC1) were identified by peptides that met the following three criteria. 1) The peptide was captured by streptavidin beads, indicating that it was originally attached to a biotin-labeled oligosaccharide structure. 2) The captured peptide contains a deamidation (0.98-Da shift). 3) The deamidation occurs at asparagine within the *N*-linked glycosylation consensus amino acid sequence motif for *N*-linked glycosylation (N*X*(S/T)). As summarized in [Fig. 3](#F3){ref-type="fig"}, 46 (36%) proteins were identified by a single unique glycopeptide, whereas 82 (64%) were identified by two or more unique glycopeptides. Of the 128 identified proteins, 117 have predicted transmembrane (TM) domains (based on the three prediction algorithms used), four are known GPI-anchored proteins, and five are known extracellular matrix (ECM) proteins. To provide an overview of the distribution of the number of TM domains per protein, the results from each topology prediction algorithm were averaged as not all algorithms predict the same number of TM domains for each protein ([supplemental Table S1](http://www.mcponline.org/cgi/content/full/M900195-MCP200/DC1)). This resulted in a total of 56, 23, and 41 proteins containing 1, 2, or ≥3 TM domains, respectively ([Fig. 3](#F3){ref-type="fig"}*C*). Interestingly, unlike other methods for isolating membrane proteins, the CSC technology was able to identify proteins with as many as 13 transmembrane domains. Importantly, designation of the proteins in the current list as "cell surface proteins" is based only on the experimental data and not on database annotations. This allows for the inclusion of cell surface proteins that are not transmembrane proteins (*i.e.* GPI-anchored) and avoids mistakenly eliminating proteins that may have incomplete/ambiguous database or gene ontology term annotations regarding their subcellular localization.

![**Characterization of *N*-linked peptides and their corresponding proteins.** *A*, pie chart showing the distribution of the number of unique *N*-linked glycopeptides identified per protein, highlighting that 64% of the proteins were identified by two or more unique glycopeptides. Because the method captures only those peptides that are glycosylated, it is not expected to identify multiple peptides per protein, and this depends on whether the site of glycosylation lies within a tryptic peptide with a suitable *m*/*z* for MS analysis. *B*, pie chart showing the distribution of the number of *N*-linked glycosylation sites identified per protein, highlighting that two or more sites were identified for 44% of the proteins. *C*, bar graph showing the distribution of the number of transmembrane domains calculated using three different prediction algorithms, SOSUI, HMMTOP, and TMAP.](zjw0110934880003){#F3}

#### New Information Regarding Glycosylation Site Occupancy

Identifying the site of glycosylation is useful for determining the orientation of a protein within the membrane as only the extracellular domains of plasma membrane proteins are *N*-linked glycosylated. As summarized in [Fig. 3](#F3){ref-type="fig"}*B*, one site of glycosylation was identified for 72 (56%) proteins, whereas two or more glycosylation sites were identified for 56 (44%) proteins. For 10 proteins, the current data identified the only potential glycosylation site; whereas for eight other proteins, all predicted glycosylation sites (*n* = 2--3) were observed ([Table I](#TI){ref-type="table"}). When determining whether the current data provided any new information regarding occupied glycosylation sites, occasionally the Swiss-Prot database predicted fewer sites than were observed in the current study. In other words, not all N*X*(S/T) sites are listed in Swiss-Prot. For those proteins, EnsembleGly ([@B60]) was used to predict the number of N*X*(S/T) motifs in the extracellular domain, and the results from that prediction are included in [Table I](#TI){ref-type="table"}. In total, of the 235 *N*-linked glycosites identified here, 226 (96%) are not documented by experimental evidence in Swiss-Prot, meaning that the current data set adds considerable new information regarding *N*-linked glycosylation site occupancy for the proteins identified. Although most glycopeptide positions were consistent with predicted protein structures, the membrane orientation provided in Swiss-Prot was inconsistent with the data observed for zinc transporter ZIP14 where the glycosylation sites identified at residues 52 and 100 are annotated as in the cytoplasmic domain. In the case of 14 proteins where the membrane orientation listed in Swiss-Prot is ambiguous (*i.e.* only transmembrane domains are predicted, but no annotations are provided regarding extracellular *versus* cytoplasmic), the findings from the current study provide evidence for the correct orientation of these proteins ([Table I](#TI){ref-type="table"}). Five proteins identified as *N*-linked glycosylated in the current study are also predicted to be *O*-linked type glycosylated: glypican-1, thrombomodulin, neuropilin-1, basement membrane-specific heparan sulfate proteoglycan core protein, and chondroitin sulfate proteoglycan 4.

###### 

N-Linked glycosite information for each protein identified via the CSC technology

The table lists the protein number (corresponds to [supplemental Table S1](http://www.mcponline.org/cgi/content/full/M900195-MCP200/DC1)), the protein name, the number of *N*-linked glycosylation sites confirmed in the current study, the number of potential *N*-linked glycosylation sites annotated in Swiss-Prot, whether these *N*-linked sites listed in Swiss-Prot are potential (*i.e.* the protein contains the N*X*(S/T) motif but no experimental evidence is available) or whether there is experimental (exp) evidence, and whether the glycopeptides identified in the current study are consistent with the extracellular domain (*i.e.* orientation) annotated in Swiss-Prot. Proteins are sorted by the number of potential *N*-linked glycosylation sites in increasing order. Y, observed glycopeptides map to predicted extracellular domain; N, observed glycopeptides map to predicted intracellular domain; NA, not applicable due to GPI or ECM; Amb, annotation regarding orientation is ambiguous. MHC, major histocompatibility complex.

  Protein number   Protein name                                                        No. identified sites   No. potential sites[^*a*^](#TFI-1){ref-type="table-fn"}   No. sites with exp evidence   Orientation consistent?   Protein number   Protein name                                                                  No. identified sites   No. potential sites[^*a*^](#TFI-1){ref-type="table-fn"}   No. sites with exp evidence   Orientation consistent?
  ---------------- ------------------------------------------------------------------- ---------------------- --------------------------------------------------------- ----------------------------- ------------------------- ---------------- ----------------------------------------------------------------------------- ---------------------- --------------------------------------------------------- ----------------------------- -------------------------
  45               Solute carrier family 2, facilitated glucose transporter member 1   1                      1                                                         0                             Y                         9                CD80 antigen                                                                  5                      6                                                         0                             Y
  63               Sphingosine 1-phosphate receptor 2 (Edg-5)                          1                      1                                                         0                             Y                         15               Ectonucleotide pyrophosphatase/phosphodiesterase family member 1              3                      6                                                         0                             Y
  70               Ephrin-A5                                                           1                      1                                                         1                             NA                        35               Neural cell adhesion molecule 1                                               1                      6                                                         1                             Y
  87               Lipid phosphate phosphohydrolase 2                                  1                      1                                                         0                             Amb                       37               Neuroplastin                                                                  3                      6                                                         1                             Y
  95               Solute carrier family 2, facilitated glucose transporter member 3   1                      1                                                         0                             Y                         48               Transmembrane protein 16F                                                     3                      6                                                         0                             Y
  99               Mast cell antigen 32                                                1                      1                                                         0                             Y                         96               Tyrosine-protein kinase receptor UFO                                          1                      6                                                         0                             Y
  113              Sphingosine 1-phosphate receptor 5 or 8                             1                      1                                                         0                             Y                         102              Cleft lip and palate transmembrane protein 1 homolog                          1                      6                                                         0                             Y
  117              Ephrin-B1                                                           1                      1                                                         0                             Y                         114              OX-2 membrane glycoprotein                                                    1                      6                                                         0                             Y
  123              Aquaporin-1                                                         1                      1                                                         0                             Y                         128              Calcitonin gene-related peptide type 1                                        1                      6                                                         0                             Y
  125              Myelin protein zero-like protein 1                                  1                      1                                                         0                             Y                         10               CD97 antigen                                                                  3                      7                                                         0                             Y
  3                Adipocyte adhesion molecule                                         1                      2                                                         0                             Y                         25               Hematopoietic progenitor cell antigen CD34                                    1                      7                                                         0                             Y
  18               Ephrin type-A receptor 2                                            2                      2                                                         0                             Y                         33               *N*-Acetylated α-linked acidic peptidase 2                                    3                      7                                                         0                             Y
  20               Excitatory amino acid transporter 1                                 2                      2                                                         0                             Y                         56               Poliovirus receptor-related protein 1                                         2                      7                                                         0                             Y
  21               Junctional adhesion molecule A                                      1                      2                                                         0                             Y                         73               Latrophilin 2                                                                 1                      7                                                         0                             Y
  44               Sodium/potassium-transporting ATPase subunit β-3                    1                      2                                                         0                             Y                         86               VPS10 domain-containing receptor SorCS2                                       1                      7                                                         0                             Y
  46               Translocon-associated protein α                                     1                      2                                                         0                             Y                         103              Cadherin-2                                                                    1                      7                                                         0                             Y
  47               Transmembrane 4 L6 family member 1                                  1                      2                                                         0                             Y                         112              Plexin A1                                                                     1                      7                                                         0                             Y
  52               Zinc transporter ZIP10                                              2                      2                                                         0                             Y                         119              Emilin-1                                                                      2                      7                                                         0                             NA
  59               Junctional adhesion molecule C                                      1                      2                                                         0                             Y                         1                4F2 cell surface antigen heavy chain                                          4                      8                                                         0                             Y
  62               Solute carrier family 12 member 2                                   1                      2                                                         0                             Y                         7                CD166 antigen                                                                 4                      8                                                         0                             Y
  67               Neutral amino acid transporter A                                    2                      2                                                         0                             Y                         23               Fibronectin                                                                   4                      8                                                         0                             NA
  79               Transmembrane 9 superfamily member 3                                1                      2                                                         0                             Y                         34               Neogenin                                                                      2                      8                                                         0                             Y
  91               Glypican-1                                                          2                      2                                                         0                             NA                        42               Prostaglandin F~2~ receptor negative regulator                                2                      8                                                         0                             Y
  104              Trophoblast glycoprotein                                            1                      2                                                         0                             Y                         16               Embigin                                                                       8                      9                                                         0                             Y
  107              Major prion protein                                                 1                      2                                                         0                             NA                        17               Endothelin-converting enzyme 1                                                3                      10                                                        0                             Y
  109              Tetraspanin-4                                                       1                      2                                                         0                             Y                         60               Tyrosine-protein kinase-like 7                                                2                      10                                                        0                             Y
  120              Transmembrane protein 87A                                           2                      2                                                         0                             Y                         122              Epidermal growth factor receptor                                              1                      10                                                        3                             Y
  6                Basigin                                                             2                      3                                                         0                             Y                         30               Integrin αV                                                                   4                      11                                                        0                             Y
  12               Choline transporter-like protein 2                                  2                      3                                                         0                             Y                         39               β-type platelet-derived growth factor receptor                                3                      11                                                        0                             Y
  19               Ephrin type-B receptor 4                                            1                      3                                                         0                             Y                         97               Lysosome membrane protein 2                                                   1                      11                                                        0                             Y
  24               H-1 class I histocompatability antigen, D-K α chain                 2                      3                                                         0                             Y                         5                Basement membrane-specific heparan sulfate proteoglycan core protein          4                      12                                                        0                             NA
  32               Macrophage mannose receptor 2                                       2                      3                                                         0                             Y                         31               Integrin β1                                                                   2                      12                                                        0                             Y
  57               Protein ITFG3                                                       3                      3                                                         0                             Y                         38               Oncostatin M-specific receptor subunit β                                      3                      12                                                        0                             Y
  80               Epithelial membrane protein 1                                       1                      3                                                         0                             Amb                       94               Receptor-type tyrosine-protein phosphatase μ                                  1                      12                                                        0                             Y
  81               Synaptophysin-like protein 1                                        1                      3                                                         0                             Y                         4                Aminopeptidase N                                                              5                      13                                                        0                             Y
  105              β-Sarcoglycan                                                       1                      3                                                         0                             Y                         27               Integrin α3                                                                   6                      13                                                        0                             Y
  106              LMBR1 domain-containing 1                                           1                      3                                                         0                             Y                         74               Lymphocyte antigen 75                                                         1                      13                                                        0                             Y
  108              CMP-*N*-acetylneuraminate-β-galactosamide-α-2,3-sialyltransferase   1                      3                                                         0                             Y                         28               Integrin α5                                                                   5                      14                                                        0                             Y
  110              Immunoglobulin superfamily member 3                                 1                      3                                                         0                             Y                         13               Chondroitin sulfate proteoglycan 4                                            5                      15                                                        0                             Y
  115              Anthrax toxin receptor 1                                            1                      3                                                         0                             Y                         65               Integrin α11                                                                  1                      16                                                        0                             Y
  127              Cadherin-10                                                         1                      3                                                         0                             Y                         88               Insulin-like growth factor 1 receptor                                         2                      16                                                        0                             Y
  11               Cell adhesion molecule 1                                            2                      4                                                         0                             Y                         69               Teneurin-3                                                                    2                      17                                                        0                             Y
  61               CD82 antigen                                                        2                      4                                                         0                             Y                         98               Leucyl-cystinyl aminopeptidase                                                1                      17                                                        0                             Y
  64               Tissue factor                                                       2                      4                                                         0                             Y                         68               Lysosomal membrane glycoprotein 1                                             1                      18                                                        2                             Y
  77               Solute carrier family 12 member 7                                   1                      4                                                         0                             Y                         72               Insulin receptor                                                              1                      18                                                        0                             Y
  78               Solute carrier family 12, member 4                                  1                      4                                                         0                             Y                         92               Cation-independent mannose 6-phosphate receptor                               1                      20                                                        0                             Y
  83               Ephrin type-B receptor 2                                            1                      4                                                         0                             Y                         126              Tenascin                                                                      1                      20                                                        1                             NA
  84               Thrombomodulin                                                      1                      4                                                         0                             Y                         82               Probable G-protein-coupled receptor 126                                       1                      23                                                        0                             Y
  85               Thrombospondin-1                                                    1                      4                                                         0                             NA                        41               Prolow density lipoprotein receptor-related protein 1                         3                      51                                                        0                             Y
  100              Kin of IRRE-like protein 1                                          1                      4                                                         0                             Y                         22               Fat 1 cadherin                                                                3                      0 ([@B30])[^*a*^](#TFI-1){ref-type="table-fn"}            0                             Amb
  101              Tetraspanin-3                                                       1                      4                                                         0                             Y                         76               Protein unc-84 homolog B                                                      1                      0 ([@B1])[^*a*^](#TFI-1){ref-type="table-fn"}             0                             Amb
  118              Transmembrane protein 87B                                           1                      4                                                         0                             Y                         14               Collectin-12                                                                  4                      0 ([@B12])[^*a*^](#TFI-1){ref-type="table-fn"}            0                             Y
  2                Acid sphingomyelinase-like phosphodiesterase 3b                     2                      5                                                         0                             NA                        40               Plexin B2                                                                     6                      0 ([@B15])[^*a*^](#TFI-1){ref-type="table-fn"}            0                             Amb
  29               Integrin α7                                                         1                      5                                                         0                             Y                         49               Transmembrane protein 2                                                       2                      0 ([@B15])[^*a*^](#TFI-1){ref-type="table-fn"}            0                             Amb
  36               Neuropilin-1                                                        2                      5                                                         0                             Y                         116              Claudin domain-containing protein 1                                           1                      0 ([@B2])[^*a*^](#TFI-1){ref-type="table-fn"}             0                             Amb
  50               Vascular cell adhesion protein 1 (isoform 1)                        2                      5                                                         0                             Y                         66               MHC H-2K-k protein                                                            1                      0 ([@B3])[^*a*^](#TFI-1){ref-type="table-fn"}             0                             Amb
  51               Voltage-dependent calcium channel subunit α-2/δ-1                   3                      5                                                         0                             Y                         90               Neurotrophin receptor-associated death domain                                 1                      0 ([@B3])[^*a*^](#TFI-1){ref-type="table-fn"}             0                             Amb
  54               Cadherin-15                                                         2                      5                                                         0                             Y                         93               Protocadherin 7                                                               1                      0 ([@B3])[^*a*^](#TFI-1){ref-type="table-fn"}             0                             Amb
  55               Cation-dependent mannose 6-phosphate receptor                       1                      5                                                         0                             Y                         26               Immunoglobulin superfamily containing leucine-rich repeat region              2                      0 ([@B4])[^*a*^](#TFI-1){ref-type="table-fn"}             0                             Amb
  58               Golgi apparatus protein 1                                           2                      5                                                         0                             Y                         53               Zinc transporter ZIP14                                                        2                      0 ([@B5])[^*a*^](#TFI-1){ref-type="table-fn"}             0                             N
  71               Fibroblast growth factor receptor 4                                 1                      5                                                         0                             Y                         89               cDNA sequence BC051070                                                        1                      0 ([@B5])[^*a*^](#TFI-1){ref-type="table-fn"}             0                             Amb
  75               P2X purinoceptor 7                                                  1                      5                                                         0                             Y                         43               Protocadherin γ C3                                                            1                      0 ([@B8])[^*a*^](#TFI-1){ref-type="table-fn"}             0                             Amb
  111              Zinc transporter ZIP6                                               1                      5                                                         0                             Y                         121              Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit STT3B   3                      0 ([@B8])[^*a*^](#TFI-1){ref-type="table-fn"}             0                             Amb
  124              Semaphorin-7A                                                       1                      5                                                         0                             NA                        8                CD276 antigen                                                                 2                      1 ([@B4])[^*a*^](#TFI-1){ref-type="table-fn"}             0                             Y

^*a*^ If no *N*-linked glycosylation sites are predicted in Swiss-Prot or if fewer are predicted than were observed, then the number of predicted *N*-linked glycosylation sites from EnsembleGly is provided. The first number is from Swiss-Prot; the number in parentheses is from EnsembleGly.

#### Comparison with Other Proteomics Studies of C2C12 Differentiation

The list of *N*-linked glycoproteins identified here was compared with the data sets from two previously published global proteomics studies of undifferentiated and differentiated C2C12 cells ([@B52], [@B53]). Although cell culture conditions, sample handling, and mass spectrometry differed among the three studies, this comparison permitted us to assess whether the CSC technology was capable of discovering novel information. Most importantly, 74% of the proteins identified via the CSC technology were not present among the \>1700 proteins identified in the previously published studies ([Fig. 4](#F4){ref-type="fig"}). Additionally, 16 proteins containing the N*X*(S/T) sequence motif (although there are no data that predict these sites are actually occupied) and predicted to be localized to the cell surface were not identified by the CSC technology. Only four of these, however, were identified in the undifferentiated myoblasts in the previous proteomic studies, whereas the other 12 were only observed in latter stages of differentiation and thus are not expected to be found in the current study. In contrast, the CSC technology identified 18 proteins in the undifferentiated state that were only observed in differentiated cells in the other proteomics studies. All 18 were identified by ≥2 spectra in the current study ([Table S6](http://www.mcponline.org/cgi/content/full/M900195-MCP200/DC1)). For example, 97 spectra were observed for CD98 in the current study, although Kislinger *et al.* ([@B53]) only identified a single spectrum for CD98 after 10 days of differentiation. This exemplifies the ability of the CSC technology to identify proteins that may be less accessible to non-targeted methods.

![**Comparison of the proteins identified by the CSC technology with those identified in other proteomics studies of C2C12 cells.** *A*, Venn diagram showing overlap of proteins identified in three proteomics studies each using different strategies to examine the mouse C2C12 myoblast proteome. In summary, 74% of proteins identified by the CSC technology were not identified in other, non-targeted studies. *B*, of the proteins identified by Kislinger *et al.* ([@B53]) and Tannu *et al.* ([@B52]) but not by the CSC technology, Venn diagrams show how many proteins are potentially *N*-linked (although no data exist to confirm their occupancy) and predicted to be cell surface proteins based on gene ontology (*GO*) term annotations, highlighting what the CSC technology may have missed. Of the 16 proteins that meet these criteria, only four were identified in undifferentiated myoblasts in the previous studies and thus could be expected to be observed in the current study. Refer to [supplemental Tables S1 and S5](http://www.mcponline.org/cgi/content/full/M900195-MCP200/DC1) for proteins identified by the CSC technology but not by Kislinger *et al.* ([@B53]) and Tannu *et al.* ([@B52]).](zjw0110934880004){#F4}

#### Biological Relevance of Identified Proteins in Skeletal Muscle Development and Repair

To identify potential proteins for follow-up studies aimed at finding markers of differentiation, a literature search of the potential biological relevance of each protein identified in the context of skeletal muscle development and repair was conducted (via PubMed), and the results are summarized in [supplemental Table S7](http://www.mcponline.org/cgi/content/full/M900195-MCP200/DC1). Interesting proteins include M-cadherin, which is differentially expressed among satellite cells, proliferating myoblasts, and differentiated myotubes ([@B61], [@B62]) and is implicated in myoblast fusion ([@B63]). Other examples include thrombospondin-1, which may play a role in myoblast attachment ([@B64]), and glypican-1, which increases during myoblast differentiation and modulates myoblast proliferation and differentiation via the fibroblast growth factor 2 pathway ([@B65][@B66]--[@B67]). The information in the [supplemental Table S7](http://www.mcponline.org/cgi/content/full/M900195-MCP200/DC1) is not intended to be an exhaustive list of the biological significance of all the proteins identified in the current study but rather to illustrate that a number of the proteins identified are known to have some relevance to skeletal muscle biology and, thus, could be targets of future follow-up studies focused on understanding the molecular events critical for skeletal muscle development and repair.

#### Protein Abundance Changes in Cell Surface Glycoproteins with Differentiation

To further refine the list of proteins that may be useful for future follow-up studies, previously published studies showing the change in protein abundance ([@B52], [@B53]) and mRNA expression ([@B55], [@B56]) of undifferentiated and differentiated C2C12 cells were analyzed to determine whether any of the proteins identified in the current study might show differential expression with differentiation. Seven mRNA transcripts and 33 proteins were reported to change in previous studies ([supplemental Tables S2 and S3](http://www.mcponline.org/cgi/content/full/M900195-MCP200/DC1)). Based on these comparisons, three proteins, aquaporin-1, β-sarcoglycan, and cadherin 2, were evaluated by Western blots to determine whether the overall abundance of these proteins changes as the cells differentiate toward myotubes. Cells were cultivated as shown in [Fig. 2](#F2){ref-type="fig"}, and samples were taken at 0, 1, 2, and 5 days after differentiation induction (low serum conditions). Western blotting confirmed the presence of aquaporin-1, β-sarcoglycan, and cadherin 2 on the undifferentiated C2C12 myoblasts; each of these proteins were identified by single peptide sequences via MS. As the myoblasts differentiated, Western blotting demonstrated a significant decrease in the overall abundance of aquaporin-1 (both glycosylated and non-glycosylated forms), a slight decrease in the overall abundance of cadherin 2, and a significant increase in the overall abundance of β-sarcoglycan ([Fig. 5](#F5){ref-type="fig"}). These results are consistent with previous genomics and proteomics studies and, when combined with what is known about their biological function, highlight the potential role these proteins may play in myoblast differentiation as well as their possible use as cell surface markers.

![**Western blotting to probe for changes in protein abundance with differentiation.** Western blot images for cadherin 2 (30 μg of total protein per lane), β-sarcoglycan (50 μg of total protein per lane), and aquaporin-1 (15 μg of total protein per lane) prepared from protein extracts of C2C12 cells grown in growth medium (*GM*) or in differentiation medium for 1, 2, or 5 days. Topoisomerase I loading control is representative for all blots. Molecular masses listed are approximate and are derived from the relationship to the molecular mass marker (not shown). For aquaporin-1, the Western blot shows both the glycosylated and non-glycosylated forms. The observed molecular mass for β-sarcoglycan is consistent with a glycosylated form, and the observed molecular mass for cadherin-2 is consistent with the non-glycosylated form.](zjw0110934880005){#F5}

Interestingly, the aquaporin-1 antibody used for Western blotting is reported to recognize both the glycosylated and non-glycosylated forms (see the product information), and this is consistent with what was observed in the current study where both forms were observed and appeared to decrease in abundance with differentiation. The molecular mass of β-sarcoglycan detected by the Western blot (∼43 kDa) is consistent with a glycosylated form as the predicted molecular mass of the native protein is ∼35 kDa. Finally, under the current conditions, only the non-glycosylated form of cadherin 2 was detected by the Western blot (both the observed and theoretical molecular mass, ∼98 kDa), although the MS data indicate that the protein is glycosylated. This may be a result of the gel and blotting experimental conditions (*i.e.* high molecular weight proteins are not transferred as efficiently), the glycosylated form may be much less abundant than the native form, or the antibody may preferentially recognize the non-glycosylated form. This exemplifies the utility of the MS-based CSC technology, which does not rely on the specificity or sensitivity of an antibody or optimization of gel conditions.

DISCUSSION
==========

Using the CSC technology, the current study identified 128 cell surface *N*-linked glycoproteins on undifferentiated mouse C2C12 myoblasts; this is the largest library of cell surface *N*-linked glycoproteins described for this cell type to date. In addition to finding *N*-linked membrane glycoproteins not previously reported to be on the surface of C2C12 myoblasts, the current work adds new information about the occupancy of predicted glycosylation sites for 122 (95%) of the proteins identified as well as new information regarding protein orientation within the membrane for the proteins identified. Finally, the study provides examples of how potential markers of differentiation can be derived by starting from a characterization of the cell surface and then augmenting the data with comparisons with what is already known about protein biology as well as other proteome and transcriptome studies.

### 

#### Uncovering a Hidden Proteome

Cell surface proteins (which include TM, GPI-anchored, and ECM proteins) are often undersampled in traditional proteomics approaches because of their relative insolubility/hydrophobicity (for TM proteins) and lower abundance compared with non-membrane proteins. To address this, a large number of studies have focused on identifying the proteins present in membrane (plasma and organelle membrane)-enriched fractions as opposed to whole cell lysates (for reviews, see Refs. [@B68][@B69]--[@B70]). However, when using general biochemical membrane preparation techniques such as density gradients and ultracentrifugation alone, the identified membrane proteins cannot be distinguished as derived from the cell surface *versus* intracellular organelle membrane based upon experimental data. This is due, in part, to the fact that it is difficult to obtain purified plasma membrane proteins without contamination from membranes from other intracellular organelles such as the nucleus, mitochondria, endoplasmic reticulum, Golgi, and lysosome. In this case, researchers typically rely on available gene ontology or protein database annotations for classifying the subcellular location of identified proteins, although this information can be missing or incomplete in addition to the fact that a single protein may have several different locations annotated, and therefore, it may not be possible to unambiguously assign the localization of the protein in the particular cell type examined for example. To overcome these challenges, a number of more targeted approaches have utilized creative solutions such as enzymatic "shaving" of extracellular domains on intact cells ([@B71][@B72][@B73][@B74][@B75][@B76]--[@B77]), fluorescent labeling ([@B78], [@B79]), lectin affinity ([@B80][@B81]--[@B82]), and biotinylation of cell surface proteins ([@B25], [@B83][@B84][@B85][@B86][@B87][@B88][@B89][@B90]--[@B91]). Each of these methods adds another level of specificity for plasma membrane proteins over intracellular membrane proteins. The approach used in the current study takes advantage of the fact that a majority of the cell surface proteins are glycosylated, thus allowing for their specific capture and ultimately allowing for the identification of cell surface proteins, which are less accessible to non-targeted methods. Most importantly, 74% of the proteins identified here have not been reported in previous global proteomics studies of the same cell type, highlighting the utility of this targeted approach, which effectively reduces sample complexity and allows for the identification of hydrophobic as well as lower abundance proteins.

#### Importance of Confirming Glycosylation Site Occupancy

Confirming glycosylation site occupancy is critical for determining the orientation of the protein within the membrane and antigen design for antibody development. Although publicly available protein databases (*e.g.* Swiss-Prot) contain information that may predict the presence of an *N*-linked glycosylation moiety due to the presence of an N*X*(S/T) sequence motif, they do not always provide conclusive experimental evidence that a potential glycosylation site is occupied ([Table I](#TI){ref-type="table"}). For 122 (95%) of the proteins identified here, none of the glycosylation sites listed in Swiss-Prot are documented by experimental evidence; thus the current data add new information regarding the occupation of these sites for most of the proteins identified. Importantly, not all occupied sites may be identified via the CSC technology as it is possible that a site may lie within a region of the protein that, after enzymatic digestion, does not result in a peptide with an appropriate *m*/*z* for detection. Thus, the absence of an identified site is not conclusive evidence that the site is not occupied. Although spontaneous or chemical deamidation at the asparagine within the N*X*(S/T) motif is possible and could lead to false positive assignments, the binding of biotin-labeled glycopeptides to the streptavidin beads enriches specifically for those peptides that are in fact glycosylated, reducing the likelihood that peptides identified in the captured fraction with deamidation at N*X*(S/T) were generated by chemical deamidation. It is further noted that there are several databases beyond Swiss-Prot that summarize experimental evidence regarding the occupancy of potential glycosylation sites (*e.g.* UniPep ([@B92]) and Human Protein Reference Database ([@B93])). However, these resources are specific for human protein data and thus could not be used to determine whether the experimental data provided here (which uses murine cells) reports new confirmations of site occupancy. Of course, these resources are useful for predicting sites that are likely occupied in homologous proteins. In general, glycosylation of cell surface proteins is critical for cell adhesion, motility, and cell-cell interactions. Specifically, previous studies have shown that glycosylation of a number of the proteins identified here affects their function. For example, glycosylation of calcitonin gene-related peptide type 1 is critical for its function as a receptor ([@B94]), glycosylation of Edg-1 affects lateralization and internalization of the receptor ([@B95], [@B96]), and glycosylation of NCAM has a role in attenuating myoblast fusion ([@B97]). Thus, the new knowledge regarding occupation of glycosylation sites may aid in further elucidating the biological implications of glycosylation for the proteins identified.

#### Potential Markers of Myoblast Differentiation

Aquaporin-1 was identified by the CSC technology in undifferentiated myoblasts but was not detected in the other proteomics studies of C2C12 differentiation ([@B52], [@B53]). Additional studies that have focused specifically on aquaporin-1 have shown the absence of aquaporin-1 on adult mouse muscle fibers ([@B98]), and similar results have been observed in rat ([@B99]), although its presence has been reported for human adult skeletal muscle ([@B100], [@B101]). The mRNA levels for aquaporin-1 were previously found to decrease significantly with myoblast differentiation ([@B55], [@B56]). Our results, which showed a decrease in the overall abundance of aquaporin-1 with differentiation, are therefore consistent with these previous studies. This change is intriguing as fluid transport, which is a function of aquaporin-1, and an increase in cell volume are important processes in muscle repair after injury (*e.g.* intense activity) ([@B102][@B103]--[@B104]).

β-Sarcoglycan was identified by four spectra (one unique peptide) via the CSC technology in undifferentiated C2C12 myoblasts and three spectra in the Kislinger *et al.* ([@B53]) proteomics study. The Kislinger *et al.* ([@B53]) study shows that the number of spectra increased from one in undifferentiated myoblasts to three after 6 days of differentiation, a trend that is consistent with the observations by Western blotting in the current study. Also consistent with these observations are previous genomics studies that show an increase in β-sarcoglycan mRNA with differentiation ([@B56]). In skeletal and cardiac muscle, β-sarcoglycan is a member of the dystrophin-associated glycoprotein complex, a complex important for signaling and protecting muscle from contraction-induced injury ([@B105]) and required for maintenance of the sarcolemma ([@B106], [@B107]). Mutations in β-sarcoglycan, as well as other sarcoglycans, are associated with muscular dystrophy ([@B108], [@B109]).

Like β-sarcoglycan, cadherin 2 also has a well known biological role in skeletal muscle. Cadherin 2 (N-cadherin) was identified via the CSC technology, although it was not detected in the other proteomics studies of C2C12 differentiation ([@B52], [@B53]). Cadherin 2 is involved in calcium-dependent myoblast fusion during myogenesis ([@B110][@B111]--[@B112]), and the cadherin 2-catenin complex has been shown to be required for promoting differentiation in skeletal muscle ([@B11], [@B110], [@B113][@B114]--[@B115]).

Taken together, aquaporin-1, β-sarcoglycan, and cadherin 2 have both potential and known roles in muscle development and repair, and thus, understanding their temporal patterns of protein expression on the cell surface, for example, may help in understanding the molecular mechanisms involved in skeletal muscle development and repair. One of the limitations currently faced is that the antibodies used in the current study were not developed against extracellular epitopes. However, if antibodies are developed that recognize the extracellular domain of the proteins, then they could be used in lineage tracing experiments, for example, because they would not require cell permeabilization. In this case, the information generated in the current study regarding orientation of the protein within the membrane as well as sites of glycosylation could aid in the development of suitable antibodies that could serve as truly valuable lineage markers.

In addition to the proteins that were shown to change in abundance with differentiation via Western blotting, several other proteins are of interest as they have also been identified in a proteomics analysis of the lipid rafts of satellite cells, which are developmental precursors of myoblasts ([@B54]). Five proteins were found in both studies ([supplemental Table S1](http://www.mcponline.org/cgi/content/full/M900195-MCP200/DC1)): CD56/NCAM, basigin/CD147, tyrosine-protein kinase-like 7, integrin β1, and neurotrophin receptor-associated death domain. Of these, NCAM is particularly interesting as a potential marker of myoblast differentiation because, as in previous studies, it was either not found or rarely found in quiescent mouse satellite cells ([@B62], [@B116]) but rather was increasingly found in differentiating satellite cells and differentiating mouse myoblasts ([@B54], [@B62]).

#### Summary and Conclusions

In general, proteomics approaches to studying the cell surface are expected to add a welcomed complement to the data generated using flow cytometry, antibody arrays, and microscopy ([@B117][@B118]--[@B119]). Specifically, approaches that provide unambiguous information regarding the localization of the protein to the cell surface will be particularly useful. This is due to the fact that markers used for the selection and subsequent expansion of a particular cell type are, ideally, naturally occurring markers that are accessible to antibody binding without disruption of the cell. Therefore, advantages offered by the CSC technology compared with other proteomics methods are the ability 1) to identify *bona fide* cell surface proteins based upon the experimental data without relying on potentially incomplete database annotations and 2) provide confirmation of the membrane orientation of proteins and modifications that will be important for epitope selection and antibody design.

The current study provides a work flow for identifying potential cell surface markers of differentiation that includes 1) a targeted approach to efficiently access the plasma membrane proteome and 2) combining the results with what is known about mRNA expression, protein expression, and biological function. In summary, the work flow begins with a characterization of the cell surface and subsequently utilizes what is known about the genome and proteome to narrow the list of interesting proteins. The proteins selected via this process were found to change in abundance with differentiation of the myoblasts toward myotubes and thus complement the collection of cell surface markers already known to characterize some of the cell types present during skeletal muscle development and repair (for reviews, see Refs. [@B2] and [@B120]). Although there are currently a number of proteins described as cell surface markers (*e.g.* CD34, NCAM, and M-cadherin) for the differentiation of myoblasts, they are often present on heterogeneous subpopulations of cell types/stages (for reviews, see Refs. [@B2] and [@B120]). Therefore, the need for refined panels of markers that can identify homogeneous populations of developmental intermediates is clear. Discovery-driven proteomics strategies, like the CSC technology, can now provide the rationale for the development of protein-specific antibodies against preselected differentiation marker candidates for subsequent single cell studies.
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